1362MO Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study
| Autor: | E.Y. Yu, S.H. Park, J.C.H. Goh, S.J. Shin, N. Mehra, R. McDermott, M.A. Sala Gonzalez, P.C. Fong, R. Greil, M. Retz, J.P. Sade, Y-H. Huang, S. Begbie, F. Rey, G. Kramer, H. Suzuki, J. Zhang, J. Kim, C.H. Poehlein, E.S. Antonarakis |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Annals of Oncology. 33:S1163-S1164 |
| ISSN: | 0923-7534 |
| DOI: | 10.1016/j.annonc.2022.07.1494 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|